China Biologic Products Inc. (CBPO) Upgraded to “Buy” by Zacks Investment Research
China Biologic Products Inc. (NASDAQ:CBPO) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Monday. The brokerage currently has a $138.00 target price on the biopharmaceutical company’s stock. Zacks Investment Research’s price target would indicate a potential upside of 12.03% from the stock’s current price.
According to Zacks, “China Biologic Products, Inc., through its indirect majority-owned subsidiary, is principally engaged in the research, development, production, manufacturing and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China. Its subsidiary, Shandong Taibang Biological Products Co. Ltd., operates from its manufacturing facility located in Taian City, Shandong Province. The Company’s principal products include its approved human albumin and immunoglobulin products. These human albumin products are mainly used to increase blood volume and its immunoglobulin products are used for the treatment and prevention of diseases. “
Several other analysts also recently commented on the company. Jefferies Group reissued a “buy” rating and issued a $136.00 price objective on shares of China Biologic Products in a research note on Friday, July 22nd. Credit Suisse Group AG raised China Biologic Products from a “neutral” rating to an “outperform” rating in a research note on Tuesday, July 5th.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/10/china-biologic-products-inc-cbpo-upgraded-to-buy-by-zacks-investment-research.html
China Biologic Products (NASDAQ:CBPO) traded up 0.38% during mid-day trading on Monday, reaching $123.18. The company had a trading volume of 76,299 shares. China Biologic Products has a 12-month low of $95.70 and a 12-month high of $144.29. The company has a market capitalization of $3.31 billion, a price-to-earnings ratio of 35.52 and a beta of 1.55. The stock has a 50-day moving average of $119.06 and a 200 day moving average of $117.07.
China Biologic Products (NASDAQ:CBPO) last issued its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported $1.26 EPS for the quarter, topping the consensus estimate of $1.16 by $0.10. The firm earned $91.40 million during the quarter, compared to the consensus estimate of $87.60 million. China Biologic Products had a return on equity of 19.65% and a net margin of 29.66%. The company’s quarterly revenue was up 15.6% compared to the same quarter last year. During the same period in the prior year, the business posted $1.06 earnings per share. On average, analysts expect that China Biologic Products will post $4.33 EPS for the current year.
In other China Biologic Products news, insider Zhijing Cbpo Liu sold 1,968 shares of the firm’s stock in a transaction on Monday, August 15th. The stock was sold at an average price of $124.32, for a total value of $244,661.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Ming Yang sold 21,092 shares of the firm’s stock in a transaction on Monday, August 15th. The stock was sold at an average price of $124.32, for a total value of $2,622,157.44. Following the completion of the sale, the chief financial officer now directly owns 24,782 shares of the company’s stock, valued at $3,080,898.24. The disclosure for this sale can be found here. Corporate insiders own 2.68% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in the company. AHL Partners LLP increased its stake in China Biologic Products by 71.0% in the fourth quarter. AHL Partners LLP now owns 7,289 shares of the biopharmaceutical company’s stock worth $1,039,000 after buying an additional 3,027 shares in the last quarter. Oberweis Asset Management Inc. increased its stake in China Biologic Products by 34.7% in the fourth quarter. Oberweis Asset Management Inc. now owns 84,885 shares of the biopharmaceutical company’s stock worth $12,093,000 after buying an additional 21,885 shares in the last quarter. William Blair Investment Management LLC increased its stake in China Biologic Products by 169.1% in the fourth quarter. William Blair Investment Management LLC now owns 275,435 shares of the biopharmaceutical company’s stock worth $39,238,000 after buying an additional 173,090 shares in the last quarter. Capital World Investors increased its stake in China Biologic Products by 78.0% in the fourth quarter. Capital World Investors now owns 1,833,294 shares of the biopharmaceutical company’s stock worth $261,171,000 after buying an additional 803,294 shares in the last quarter. Finally, Ariose Capital Management Ltd purchased a new stake in China Biologic Products during the fourth quarter worth about $35,228,000. 71.71% of the stock is owned by institutional investors and hedge funds.
About China Biologic Products
China Biologic Products, Inc (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates in the manufacture and sales of human plasma products segment. It has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across over nine categories.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related companies with MarketBeat.com's FREE daily email newsletter.